Applications are now invited for the position of statistician at the NCPE. Expressions of interest are sought for candidates for a HRB funded post-doctoral position. Click here for further information
Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.
Following NCPE assessment Migalastat (Galafold®) is considered cost-effective and reimbursement is recommended subject to continuing availability of a patient access scheme.